Looking to the future of research in pediatric anxiety disorders

Depression and Anxiety

Volumn 28, Issue 1, 2011, Pages 88-98

  March, John S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anxiety disorders; biomarkers; clinical trials; developmental neuroscience; healthcare policy

Indexed keywords

BIOLOGICAL MARKER; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; ANXIETY DISORDERS ASSOCIATION OF AMERICA; CHILD; CLINICAL RESEARCH; COGNITIVE THERAPY; COMPARATIVE STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; MEDICAL SOCIETY; PEDIATRICS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSLATIONAL RESEARCH;

ANXIETY DISORDERS; AROUSAL; BRAIN; CHILD; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FEAR; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; UNITED STATES;

EID: 78651400506     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20754     Document Type: Review

References (111)

1. Angold A, Egger HL,. Preschool psychopathology: lessons for the lifespan. J Child Psychol Psychiatry 2007; 48: 961-966.
2. Copeland WE, Shanahan L, Costello EJ, Angold A,. Childhood and adolescent psychiatric disorders as predictors of young adult disorders. Archives of General Psychiatry 2009; 66: 764-772.
3. Costello EJ, Egger HL, Angold A,. The developmental epidemiology of anxiety disorders: phenomenology, prevalence, and comorbidity. Child Adolesc Psychiatr Clin N Am 2005; 14: 631-648, vii.
4. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE,. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602. (Pubitemid 40973434)
5. NAMHC. 2008. Transformative Neurodevelopmental Research in Mental Illness. Washington, DC: NIMH.
6. Insel TR,. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009; 66 (2): 128-133.
7. Bale TL, Baram TZ, Brown AS, et al. Early life programming and neurodevelopmental disorders. Biol Psychiatry 2010; 68: 314-319.
8. Brady LS, Giffin RB, Woodcock J, Cassell GH, Holmes EW,. Grand challenges for psychiatric drug discovery: a perspective. Neuropsychopharmacology 2008; 33: 2047.
9. Pine DS, Helfinstein SM, Bar-Haim Y, Nelson E, Fox NA,. Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety. Neuropsychopharmacology 2009; 34: 213-228.
10. Zerhouni EA,. Clinical research at a crossroads: the NIH roadmap. J Investig Med 2006; 54: 171-173.
11. Olsen L, Aisner D, McGinnis JM., The Learning Health Care System: Workshop Summary. Washington, DC: National Academies Press; 2007.
12. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol 2002; 40: 1895-1901.
13. Jenders RA, Osheroff JA, Sittig DF, Pifer EA, Teich JM,. Recommendations for clinical decision support deployment: synthesis of a roundtable of medical directors of information systems. AMIA Annu Symp Proc 2007; 359-363.
14. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9: 203-214.
15. Agid Y, Buzsaki G, Diamond DM, Frackowiak R, Giedd J, Girault JA, et al. How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 2007; 6 (3): 189-201.
16. Munos B,. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009; 8: 959-968.
17. Nierenberg AA,. The perfect storm: CNS drug development in trouble. CNS Spectr 2010; 15: 282-283.
18. Brady LS, Winsky L, Goodman W, Oliveri ME, Stover E,. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacology 2009; 34: 229-243.
19. NAMHC. 2010. From Discovery to Cure: Accellerating the Development of New and Personalized Interventions for Mental Illness. Washington, DC: NIMH.
20. March JS,. The future of psychotherapy for mentally ill children and adolescents. J Child Psychol Psychiatry 2009; 50: 170-179.
21. DeVeaugh-Geiss J, March J, Shapiro M, et al. Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psychiatry 2006; 45: 261-270.
22. Murray DW, Arnold LE, Swanson J, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep 2008; 10: 424-431.
23. POTS. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Jama 2004; 292: 1969-1976.
24. Freeman JB, Choate-Summers ML, Garcia AM, et al. The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods. Child Adolesc Psychiatry Ment Health 2009; 3: 4.
25. March JS, Vitiello B,. Clinical messages from the Treatment for Adolescents With Depression Study (TADS). Am J Psychiatry 2009; 166: 1118-1123.
26. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359: 2753-2766.
27. March J, Silva S, Compton S, Shapiro M, Califf R, Krishnan R,. The case for practical clinical trials in psychiatry. American Journal of Psychiatry 2005; 162: 836-846.
28. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol 2009; 62: 464-475.
29. March JS, Swanson JM, Arnold L, et al. Anxiety as a predictor and outcome variable in the Multimodal Treatment Study of Children with ADHD (MTA). Journal of Abnormal Child Psychology 2000; 28: 527-541.
30. Franklin ME, March JS, Garcia A., Treating Obsessive-Compulsive Disorder in Children and Adolescents. In:, Antony MM, Purdon C, Summerfeldt LJ, editors. Psychological treatment of obsessive compulsive disorders: Fundamentals and beyond. DC, US: American Psychological Association; 2007: 253-266.
31. Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35: 1304-1313.
32. Team T,. Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003; 42: 531-542.
33. Baigent C,. The need for large-scale randomized evidence. Br J Clin Pharmacol 1997; 43: 349-353.
34. Compton SN, March JS, Brent D, Albano AM, Weersing R, Curry J,. Cognitive-Behavioral Psychotherapy for Anxiety and Depressive Disorders in Children and Adolescents: An Evidence-Based Medicine Review. J Am Acad Child Adolesc Psychiatry 2004; 43: 930-959.
35. Compton SN, Kratochvil CJ, March JS,. Pharmacotherapy for anxiety disorders in children and adolescents: an evidence-based medicine review. Pediatr Ann 2007; 36: 586-590, 592, 594-598.
36. Pine DS,. Integrating research on development and fear learning: a vision for clinical neuroscience? Depress Anxiety 2009; 26: 775-779.
37. Levitt P,. Developmental neurobiology and clinical disorders: lost in translation? Neuron 2005; 46: 407-412.
38. Nelson CA, Bloom FE, Cameron JL, Amaral D, Dahl RE, Pine D,. An integrative, multidisciplinary approach to the study of brain-behavior relations in the context of typical and atypical development. Dev Psychopathol 2002; 14: 499-520.
39. Insel TR,. From animal models to model animals. Biol Psychiatry 2007; 62: 1337-1339.
40. Gross C, Zhuang X, Stark K, et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002; 416: 396-400.
41. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-389.
42. Kaffman A, Meaney MJ,. Neurodevelopmental sequelae of postnatal maternal care in rodents: clinical and research implications of molecular insights. J Child Psychol Psychiatry 2007; 48: 224-244.
43. Sah DW,. Therapeutic potential of RNA interference for neurological disorders. Life Sci 2006; 79: 1773-1780.
44. Casey BJ, Nigg JT, Durston S,. New potential leads in the biology and treatment of attention deficit-hyperactivity disorder. Curr Opin Neurol 2007; 20: 119-124.
45. Fossella JA, Casey BJ,. Genes, brain, and behavior: bridging disciplines. Cogn Affect Behav Neurosci 2006; 6: 1-8.
46. Wang PS, Heinssen R, Oliveri M, Wagner A, Goodman W,. Bridging bench and practice: translational research for schizophrenia and other psychotic disorders. Neuropsychopharmacology 2009; 34: 204-212.
47. Baughman RW, Farkas R, Guzman M, Huerta MF,. The National Institutes of Health Blueprint for Neuroscience Research. J Neurosci 2006; 26: 10329-10331.
48. Kuehn BM,. NIH program to boost pipeline for drugs to treat rare and neglected diseases. JAMA 2009; 302: 133-134.
49. Badman D,. NIH assistance for new therapeutic development: NIH-RAID pilot program. Journal of Commercial Biotechnology 2009; 15: 12-15.
50. Zerhouni EA, Alving B,. Clinical and translational science awards: a framework for a national research agenda. Transl Res 2006; 148: 4-5.
51. Dzau VJ, Ackerly DC, Sutton-Wallace P, et al. The role of academic health science systems in the transformation of medicine. Lancet 2010; 375 (9718): 949-953.
52. i2b2. Informatics for Integrating Biology & the Bedside, a National Center for Biomedical Computing; 2009.
53. Ohmann C, Kuchinke W,. Future developments of medical informatics from the viewpoint of networked clinical research. Interoperability and integration. Methods Inf Med 2009; 48: 45-54.
54. Insel TR, Scolnick EM,. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006; 11 (1): 11-17.
55. Davis M, Hanson S, Altevogt B., Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary. Washington, DC: National Academies Press; 2008.
56. de Leon J,. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009; 34: 159-172.
57. ScienceMag.org. Systems Biology. Science 2002; 295 (5560).
58. Holsboer F,. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 2008; 9 (8): 638-646.
59. Burke W, Psaty BM,. Personalized medicine in the era of genomics. JAMA 2007; 298: 1682-1684.
60. Malhotra AK, Lencz T, Correll CU, Kane JM,. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 2007; 19: 523-530.
61. IOM. Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities. Washington, DC: Institute of Medicine; 2009.
62. Collins F,. Francis Collins interview. Departing U.S. genome institute director takes stock of personalized medicine. Interview by Jocelyn Kaiser. Science 2008; 320: 1272.
63. Hughes B,. Developing tools for stratified medicine. Nat Rev Drug Discov 2009; 8: 919-920.
64. Trusheim MR, Berndt ER, Douglas FL,. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007; 6: 287-293.
65. Bearer CF, Bailey SM, Hoek JB,. Advancing alcohol biomarkers research. Alcohol Clin Exp Res 2010; 34: 941-945.
66. Conn P, Roth B,. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 2008; 33: 2048-2060.
67. Lazo JS, Brady LS, Dingledine R,. Building a pharmacological lexicon: small molecule discovery in academia. Mol Pharmacol 2007; 72: 1-7.
68. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ,. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97-100.
69. Hinman L, Spear B, Tsuchihashi Z, et al. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop. Pharmacogenomics 2009; 10: 127-136.
70. Kaddurah-Daouk R, Krishnan KR,. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009; 34: 173-186.
71. Cummings JL,. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 2010; 31 (8): 1481-1492.
72. Shaw P, Lerch JP, Pruessner JC, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol 2007; 6: 494-500.
73. Citron M,. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010; 9: 387-398.
74. Krishnan V, Nestler EJ,. The molecular neurobiology of depression. Nature 2008; 455 (7215): 894-902.
75. Gobburu JV,. Biomarkers in clinical drug development. Clin Pharmacol Ther 2009; 86: 26-27.
76. Altar CA,. The Biomarkers Consortium: on the critical path of drug discovery. Clin Pharmacol Ther 2008; 83: 361-364.
77. Wagner JA,. Biomarkers: principles, policies, and practice. Clin Pharmacol Ther 2009; 86: 3-7.
78. Woodcock J,. Chutes and ladders on the critical path: comparative effectiveness, product value, and the use of biomarkers in drug development. Clin Pharmacol Ther 2009; 86: 12-14.
79. Wadman M,. NIH encourages translational collaboration with industry. Nat Rev Drug Discov 2010; 9: 255-256.
80. Eck SL, Paul SM,. Biomarker qualification via public-private partnerships. Clin Pharmacol Ther 2010; 87: 21-23.
81. Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA,. Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. Health Aff (Millwood) 2007; 26: 62-74.
82. Munos BH, Chin WW,. A call for sharing: adapting pharmaceutical research to new realities. Sci Transl Med 2009; 1: 9cm8.
83. Armitage P,. Attitudes in clinical trials. Stat Med 1998; 17: 2675-2683.
84. Treweek S, Zwarenstein M,. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials 2009; 10: 37.
85. Depp C, Lebowitz BD,. Clinical trials: bridging the gap between efficacy and effectiveness. Int Rev Psychiatry 2007; 19: 531-539.
86. Hughes B,. 2009 FDA drug approvals. Nat Rev Drug Discov 2010; 9 (2): 89-92.
87. Ng R., Drugs: From Discovery to Approval. Hoboken, NU: Wiley: Blackwell; 2008.
88. Orloff J, Douglas F, Pinheiro J, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009; 8: 949-957.
89. Chang M, Chow SC, Pong A,. Adaptive design in clinical research: issues, opportunities, and recommendations. J Biopharm Stat 2006; 16: 299-309; discussion 311-2.
90. Chow SC, Chang M,. Adaptive design methods in clinical trials-a review. Orphanet J Rare Dis 2008; 3: 11.
91. Chow SC, Tse SK, Lin M,. Statistical methods in translational medicine. J Formos Med Assoc 2008; 107: 61-73.
92. Murphy SA, Collins LM, Rush AJ,. Customizing treatment to the patient: adaptive treatment strategies. Drug Alcohol Depend 2007; 88: S1-S3.
93. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P,. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748-751.
94. Bar-Haim Y,. Research review: Attention bias modification (ABM): a novel treatment for anxiety disorders. J Child Psychol Psychiatry 2010; 51: 859-870.
95. Schoenmakers TM, de Bruin M, Lux IF, Goertz AG, Van Kerkhof DH, Wiers RW,. Clinical effectiveness of attentional bias modification training in abstinent alcoholic patients. Drug Alcohol Depend 2010; 109: 30-36.
96. Angelakis E, Hatzis A, Panourias IG, Sakas DE,. Brain-computer interface: a reciprocal self-regulated neuromodulation. Acta Neurochir Suppl 2007; 97: 555-559.
97. Lim CG, Lee TS, Guan C, et al. Effectiveness of a Brain-Computer Interface Based Programme for the Treatment of ADHD: A Pilot Study. Psychopharmacol Bull 2010; 43: 73-82.
98. Behar E, McHugh RK, Peckham A, Otto MW,. D-cycloserine for the augmentation of an attentional training intervention for trait anxiety. J Anxiety Disord 2010; 24: 440-445.
99. Tunis S, Clancy C, Helms WD, McGinnis JM, Pearson SD,. Roundtable on expanding capacity for comparative effectiveness research in the United States: discussion took place on June 3, 2007, at the Academy Health Annual Research Meeting in Orlando, FL. Health Serv Res 2009; 44: 327-342.
100. March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R,. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162: 836-846.
101. Tunis SR, Stryer DB, Clancy CM,. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Jama 2003; 290: 1624-1632.
102. Garber AM, Tunis SR,. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 2009; 360: 1925-1927.
103. Wang PS, Ulbricht CM, Schoenbaum M,. Improving mental health treatments through comparative effectiveness research. Health Aff (Millwood) 2009; 28: 783-791.
104. Timmermans S, Mauck A,. The promises and pitfalls of evidence-based medicine. Health Aff (Millwood) 2005; 24: 18-28.
105. Lohr KN,. Guidelines for clinical practice: applications for primary care. Int J Qual Health Care 1994; 6: 17-25.
106. Lohr KN,. Guidelines for clinical practice: what they are and why they count. J Law Med Ethics 1995; 23: 49-56.
107. Lohr KN,. Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 2004; 16: 9-18.
108. Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A, Detmer DE,. A roadmap for national action on clinical decision support. J Am Med Inform Assoc 2007; 14: 141-145.
109. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119-142. (Pubitemid 38230109)
110. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73-82.
111. Insel TR,. Disruptive insights in psychiatry: transforming a clinical discipline. J Clin Invest 2009; 119: 700-705.